Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Oct 15, 2026; 18(10): 121184
Published online Oct 15, 2026. doi: 10.4251/wjgo.121184
Published online Oct 15, 2026. doi: 10.4251/wjgo.121184
Clinical application of a programmed death ligand-1 inhibitor combined with low-dose pulsed radiotherapy in recurrent metastatic hepatocellular carcinoma
Xin-An Wan, Le Yuan, Hang Zhang, Dan Wang, Zhao-Di Liu, Department of Oncology, The Second People’s Hospital, Wuhu, Wuhu 241000, Anhui Province, China
Ming-Xing Fang, Department of Anesthesiology, The Second People’s Hospital, Wuhu, Wuhu 241000, Anhui Province, China
Author contributions: Wan XA designed the study, supervised the study and revised the manuscript; Fang MX collected data and drafted the manuscript; Yuan L, Zhang H, Wang D, and Liu ZD contributed to patient recruitment, follow-up and acquisition of data; all authors have read and approve the final manuscript.
AI contribution statement: AI tools were used solely for linguistic refinement and formatting assistance. No AI tool was involved in the generation of research data, interpretation of results, or formulation of conclusions. All AI-generated outputs were critically reviewed and revised by the authors.
Supported by Clinical Medical Research Transformation Project of Anhui Province of China, No. 202204295107020064.
Institutional review board statement: The study was reviewed and approved by the Ethics Committee of the Second People’s Hospital, Wuhu (approval No. 2024-KY-41).
Clinical trial registration statement: This trial was not registered. The local institutional review board was aware of the trial and approved study.
Informed consent statement: All participants provided informed consent.
Conflict-of-interest statement: All authors declare no conflict of interest in publishing the manuscript.
CONSORT 2010 statement: The authors have read the CONSORT 2010 Statement, and the manuscript was prepared and revised according to the CONSORT 2010 Statement.
Data sharing statement: Technical appendix and dataset available from the corresponding author.
Corresponding author: Xin-An Wan, MD, PhD, Chief Physician, Department of Oncology, The Second People’s Hospital, Wuhu, No. 6 Duchun Road, Wuhu 241000, Anhui Province, China. 2263853630@qq.com
Received: March 18, 2026
Revised: June 16, 2026
Accepted: July 9, 2026
Published online: October 15, 2026
Processing time: 182 Days and 19.8 Hours
Revised: June 16, 2026
Accepted: July 9, 2026
Published online: October 15, 2026
Processing time: 182 Days and 19.8 Hours
Core Tip
Core Tip: The combination of a programmed death ligand-1 inhibitor (atezolizumab) and low-dose pulsed radiation therapy has shown good efficacy and safety in some patients with recurrent metastatic hepatocellular carcinoma.